Crossmark

5-Bromouracil-gracillin (5BrU-G) complex: an APOBEC3-activated therapeutic strategy exploiting cancer-specific enzymatic activity for selective cytotoxicity

Crossref DOI link: https://doi.org/10.1007/s12032-025-02745-x

Published Online: 2025-05-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hatim, Mays S.

Al-Saffar, Ali Z. https://orcid.org/0000-0001-6398-2193
Al-Aadhami, Mohammad Abdul Wahab Shaker https://orcid.org/0000-0001-5233-1475
License Information

Text and Data Mining valid from 2025-05-08

Version of Record valid from 2025-05-08
More Information

Article History

Received: 17 February 2025

Accepted: 25 April 2025

First Online: 8 May 2025

Declarations

:

: The authors assert that they do not recognize competing financial interests or personal ties that may have seemingly influenced the work presented in this study.

Document is current

Any future updates will be listed below